Vitrolife interim report January - September 2003

Vitrolife interim report January - September 2003 · Net sales for the group amounted to SEK 72.3 million (85.5) where 28.5 are assigned to business disposed 2002. Gross margin increased to 64% (52%), the group's operating result totalled SEK 38.8 million (-12.2). · Net sales for core activities increased by 27% to a total of SEK 72.3 million (57.0) and gross result increased by 56 % to SEK 46.3 million (29.5), the operating result amounted to SEK 3.7 million (-26.6). · The group's net result totalled SEK 39.6 million (-8.7). · Vitrolife sells subsidiaries A-life Ltd and A-life Inc for 60 MSEK plus royalty to Mentor Corp., USA. · Reduction of the share premium reserve of SEK 292 million settled. · Result per share amounted to SEK 2.16 (-0.47). Gothenburg, October 22, 2003. Vitrolife AB (Publ) For further information, please contact: Vitrolife CEO: Magnus Nilsson Tel: +46 31 721 80 00 Mobile +46 708 22 80 61 mnilsson@vitrolife.com CFO and IR agent: Margareta Fischer Tel: +46 31 721 80 00 Mobile: +46 708 22 80 13 mfischer@vitrolife.com Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and two wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado). The group's operations focused on three geographic areas. · Europe/Middle East · The Americas · Rest of the World Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/10/21/20041110BIT21620/wkr0001.pdf The full report in Swedish

About Us

Vitrolife is an international medical device Group. The Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. Vitrolife has approximately 330 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.

Subscribe

Documents & Links